Deferasirox in a refractory anemia after other treatment options: case report and literature review

Clinical Case Reports

¹ 

关键词: Acute myeloid leukemia;    Deferasirox;    hematological improvement;    iron overload;    myelodysplastic syndrome;   

DOI  :  10.1002/ccr3.262

来源: Wiley

【 摘 要 】

Key Clinical Message

Deferasirox, represents an effective iron chelator drug in lower risk myelodysplastic syndromes. Reduction in oxidative stress is responsible of the hematologic improvement but further explanation may impact on its benefit. Biological and clinical studies are necessary to better define mechanisms of action, assess toxicities, and predicting factors of response.

【 授权许可】

CC BY-NC   
© 2015 The Author. Clinical Case Reports published by John Wiley & Sons Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.